Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies
The DOI matches its Crossref record; 350 of the 352 references it cites were found in a registry or an index.
Abstract
This review brings you up-to-date with the hepatocyte research on: 1) in vitro-in vivo correlations of metabolism and clearance; 2) CYP enzyme induction, regulation, and cross-talk using human hepatocytes and hepatocyte-like cell lines; 3) the function and regulation of hepatic transporters and models used to elucidate their role in drug clearance; 4) mechanisms and examples of idiosyncratic and intrinsic hepatotoxicity; and 5) alternative cell systems to primary human hepatocytes. We also report pharmaceutical perspectives of these topics and compare methods and interpretations for the drug development process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. (2002) · Nature · doi:10.1038/nature00870 · Cited by 5,518 · cited 2×
“, 2002) and that they “had phenobarbital-inducible cytochrome P450” (Jiang et al., 2002).”
BackgroundRetractedPhysiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926 · cited 2×
“Almost all predictions for human clearance are made using 120 million cells/g liver weight (Andersson et al., 2001; Bachmann et al., 2003; Bayliss et al., 1999; Davies and Morris 1993; Fisher et al., 2002; Iwatsubo et al., 1997; Lave et al., 1997; McGinnity et al., 2004; Naritomi et al., 2003; Salonen et al., 2003; So…”
BackgroundMethodShimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227 · cited 1×
“More than 600 current drugs have the potential to cause liver injury in man and DILI is increasingly recognized as a major cause of serious illness (including acute fulminant hepatic failure or chronic persistent liver damage that ultimately may require transplantation) (Ostapowicz et al., 2002).”
BackgroundNELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., et al. (1993) · DNA and Cell Biology · doi:10.1089/dna.1993.12.1 · Cited by 1,655
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576 · cited 1×
“…(RXR for both PXR and CAR) and then bind to the target xenobiotic response elements (XRE) located in both the proximal and distal P450 gene promoters, resulting in the transcription of the respective CYP isoform (Goodwin et al., 1999; Lehmann et al., 1998; Moore et al., 2000; Sueyoshi et al.,”
BackgroundWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 2×
“The unbound intracellular concentration may differ from that in the external medium due to transporter-mediated uptake; the consequences of this are not necessarily intuitive (Wu and Benet, 2005).”
BackgroundInfection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., & Guguen-Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,282 · cited 14×
“Recent advances in hepatocyte-like cell lines have been obtained by the use of HepaRG cells derived from a human hepatocellular carcinoma (Aninat et al., 2006; Gripon et al., 2002).”
InfluentialBurke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., & Mayer, R. T. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90355-7 · Cited by 1,275
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · cited 2×
“It must be kept in mind that compounds may also be metabolized by extra-hepatic organs, especially drugs undergoing extensive conjugation (Obach, 1999; Soars et al., 2002).”
BackgroundMethodIngelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108 · cited 2×
“clinical practice (Smith et al., 1998, Ingelman-Sundberg, 2005).”
BackgroundIdiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054 · cited 5×
“17; Kaplowitz, 2005).”
BackgroundInfluentialMultidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Austin Doyle, L., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,051
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009 · cited 1×
“Importantly, clinical data have demonstrated the implications of drug transporter polymorphisms for the pharmacokinetics of drugs (Kim et al., 2001; Nishizato et al., 2003).”
BackgroundUtility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925 · cited 2×
“Most researchers use the well-stirred model for scaling up CLint (expressed as μl/min/million cells) to hepatic clearance in vivo (expressed as ml/min/kg body weight) (Blanchard et al., 2006; Houston, 1994; Iwatsubo et al., 1997; Obach, 1999).”
BackgroundMethodThe Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Kliewer, S. A., Goodwin, B., & Willson, T. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0038 · Cited by 921 · cited 1×
“Inducers of PXR-mediated CYP3A4 include natural glucocorticoids and synthetic steroids as well as a wide spectrum of xenobiotics (Drocourt et al., 2001; Goodwin et al., 2002; Kliewer et al., 2002; Waxman, 1999).”
BackgroundIn vitro Hepatic Differentiation of Human Mesenchymal Stem Cells
Lee, K., Kuo, T. K., Whang–Peng, J., Chung, Y., Lin, C., Chou, S., Chen, J., Chen, Y., & Lee, O. K. (2004) · Hepatology · doi:10.1002/hep.20469 · Cited by 865 · cited 2×
“Experiments aimed at differentiating different human extra-hepatic stem cells to hepatocytes have been performed by a relatively large number of groups (Avital et al., 2001; Eberhardt et al., 2006; Fiegel et al., 2003; Lavon et al., 2004; Lee et al., 2004; von Mach et al., 2004; Zulewski et al., 2001).”
BackgroundSchwartz, R. E., Reyes, M., Koodie, L., Jiang, Y., Blackstad, M., Lund, T., Lenvik, T., Johnson, S., Hu, W.-S., & Verfaillie, C. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215182 · Cited by 863 · cited 3×
“The group of verfaillie reported that “multipotent adult progenitor cells (MAPCs) differentiate into functional hepatocyte-like cells” (Schwartz et al., 2002) and that they “had phenobarbital-inducible cytochrome P450” (Jiang et al.”
BackgroundInhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829 · cited 6×
“The regulation and the mechanisms of induction of CYPs have been extensively reviewed (Hollenberg, 2002; Lin and Lu, 1998; Tang et al., 2005).”
BackgroundInfluentialMoore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001215200 · Cited by 815 · cited 1×
“…(RXR for both PXR and CAR) and then bind to the target xenobiotic response elements (XRE) located in both the proximal and distal P450 gene promoters, resulting in the transcription of the respective CYP isoform (Goodwin et al., 1999; Lehmann et al., 1998; Moore et al., 2000; Sueyoshi et al.,”
BackgroundZulewski, H., Abraham, E. J., Gerlach, M. J., Daniel, P. B., Moritz, W., Müller, B., Vallejo, M., Thomas, M. K., & Habener, J. F. (2001) · Diabetes · doi:10.2337/diabetes.50.3.521 · Cited by 785 · cited 2×
“Experiments aimed at differentiating different human extra-hepatic stem cells to hepatocytes have been performed by a relatively large number of groups (Avital et al., 2001; Eberhardt et al., 2006; Fiegel et al., 2003; Lavon et al., 2004; Lee et al., 2004; von Mach et al., 2004; Zulewski et al., 2001).”
BackgroundWaxman, D. J. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1351 · Cited by 753 · cited 1×
“Inducers of PXR-mediated CYP3A4 include natural glucocorticoids and synthetic steroids as well as a wide spectrum of xenobiotics (Drocourt et al., 2001; Goodwin et al., 2002; Kliewer et al., 2002; Waxman, 1999).”
BackgroundAninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouët, S., Morel, F., Guguen-Guillouzo, C., & Guillouzo, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006759 · Cited by 703 · cited 15×
“Recent advances in hepatocyte-like cell lines have been obtained by the use of HepaRG cells derived from a human hepatocellular carcinoma (Aninat et al., 2006; Gripon et al., 2002).”
BackgroundInfluentialSelf-citationLong‐Term in Vitro Function of Adult Hepatocytes in a Collagen Sandwich Configuration
Dunn, J. C. Y., Tompkins, R. G., & Yarmush, M. L. (1991) · Biotechnology Progress · doi:10.1021/bp00009a007 · Cited by 694 · cited 2×
“…hepatocytes in a sandwich configuration between two layers of gelled extracellular matrix proteins, with collagen I and matrigel being the most commonly used, has dramatically prolonged the longevity of cultures displaying hepatocyte-specific functions (Dunn et al., 1991; Richert et al., 2002).”
BackgroundResultThe Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6043 · Cited by 668
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity
Fromenty, B., & Pessayre, D. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00012-6 · Cited by 665
Enterohepatic bile salt transporters in normal physiology and liver disease
Kullak-ublick, G. A., Stieger, B., & Meier, P. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.06.005 · Cited by 658
Goodwin, B., Hodgson, E., & Liddle, C. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12400-5 · Cited by 646 · cited 1×
“…(RXR for both PXR and CAR) and then bind to the target xenobiotic response elements (XRE) located in both the proximal and distal P450 gene promoters, resulting in the transcription of the respective CYP isoform (Goodwin et al., 1999; Lehmann et al., 1998; Moore et al., 2000; Sueyoshi et al.,”
BackgroundTirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626 · cited 1×
“For example, rifampin is taken up into hepatocytes by OATP 1B1, which has been shown to exhibit a number of variants (Tirona et al., 2001).”
BackgroundStieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., & Meier, P. J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70224-1 · Cited by 582 · cited 20×
“In addition, DILI due to licensed drugs is an important cause of adverse drug reactions in man.”
BackgroundInfluentialHematopoietic stem cells convert into liver cells within days without fusion
Jang, Y.-Y., Collector, M. I., Baylin, S. B., Diehl, A. M., & Sharkis, S. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1132 · Cited by 553 · cited 2×
“The expression of all markers increased over time, with the exception of αFP which initially increased and later decreased, indicating possible maturation (Jang et al., 2004).”
BackgroundGUGUENGUILLOUZO, C., CLEMENT, B., BAFFET, G., BEAUMONT, C., MORELCHANY, E., GLAISE, D., & GUILLOUZO, A. (1983) · Experimental Cell Research · doi:10.1016/0014-4827(83)90107-6 · Cited by 519 · cited 1×
“Human hepatocyte cultures are normally allowed 48 h to establish good cell-cell contact, a critical characteristic for differentiation (Corlu et al., 1991; Guguen-Guillouzo et al., 1983) and induction potential (Maurel, 1996).”
BackgroundSelf-citationNishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511 · cited 1×
“Importantly, clinical data have demonstrated the implications of drug transporter polymorphisms for the pharmacokinetics of drugs (Kim et al., 2001; Nishizato et al., 2003).”
BackgroundReciprocal activation of Xenobiotic response genes by nuclear receptors SXR/PXR and CAR
Xie, W., Barwick, J. L., Simon, C. M., Pierce, A. M., Safe, S., Blumberg, B., Guzelian, P. S., & Evans, R. M. (2000) · Genes & Development · doi:10.1101/gad.846800 · Cited by 508
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496 · cited 1×
“There is now an increasing evidence that drug transporters in the liver play a key role in the pharmacokinetics of some compounds (Shitara et al., 2006).”
BackgroundPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479 · cited 3×
“Most researchers use the well-stirred model for scaling up CLint (expressed as μl/min/million cells) to hepatic clearance in vivo (expressed as ml/min/kg body weight) (Blanchard et al., 2006; Houston, 1994; Iwatsubo et al., 1997; Obach, 1999).”
BackgroundMethodLeCluyse, E. L. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00135-x · Cited by 477 · cited 3×
“In summary, it can be reasonably considered that human hepatocytes reflect the heterogeneity of P450 expression in human liver and constitute an invaluable tool for preclinical metabolic and toxicity testing of new chemical entities (Donato et al., 1995; Gomez-Lechón et al., 2004; LeCluyse, 2001).”
BackgroundSelf-citationA human peripheral blood monocyte-derived subset acts as pluripotent stem cells
Zhao, Y., Glesne, D., & Huberman, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536882100 · Cited by 467 · cited 1×
“Recently, three studies have been performed to reprogram human peripheral blood monocytes and differentiate them to hepatocytes (Ruhnke et al., 2005a,b; Zhao et al., 2003).”
BackgroundTHE ROLE OF METABOLIC ACTIVATION IN DRUG-INDUCED HEPATOTOXICITY
Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., & Williams, D. P. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100058 · Cited by 453 · cited 2×
“This may mediate cell toxicity directly (e.g. paracetamol) or may trigger adaptive immune responses in susceptible patients that are targeted against metabolite-modified liver protein neoantigens and cause immune-mediated liver injury (e.g., halothane and dihydralazine (Park et al., 2005).”
BackgroundContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443 · cited 2×
“One such example is pitavastatin, a novel potent 3-hydroxymethylglutaryl-CoA reductase inhibitor (Hirano et al., 2004).”
BackgroundRodríguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, J. V., & Gómez-Lechón, M.-J. (2002) · Xenobiotica · doi:10.1080/00498250210128675 · Cited by 420 · cited 1×
“…actively express a full set of P450s, as well as phase 2 drug-metabolizing enzymes, although they show a gradual decrease in CYP expression over time, probably due to the adaptation of cells to the culture environment (LeCluyse, 2001; Rodríguez-Antona et al., 2002; Gómez-Lechón et al., 2004).”
BackgroundWhy Drugs Fail - A Study on Side Effects in New Chemical Entities
Schuster, D., Laggner, C., & Langer, T. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414510 · Cited by 417 · cited 1×
“Unsatisfactory pharmacokinetic properties have been identified as a major reason for the failure of new chemical entities in drug development in man (Schuster et al., 2005).”
BackgroundHesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397 · cited 2×
“…the metabolism of more than 25% of all pharmaceutical drug metabolism (Code et al., 1997; Ekins and Wrighton, 1999; Faucette et al., 2000; Hanna et al., 2000; Hesse et al., 2000; Stresser and Kupfer, 1999) and exhibit high inducibility (Drocourt et al., 2001; Wang et al., 2003; Xie et al., 2000).”
BackgroundPARKINSON, A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.010 · Cited by 386 · cited 16×
“Therefore, in addition to testing those CYPs involved in the metabolism of the compound, other enzymes should be considered.”
BackgroundInfluentialLiver cell models in in vitro toxicology.
Guillouzo, A. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106511 · Cited by 385
Self-citationPascussi, J.-M., Drocourt, L., Fabre, J.-M., Maurel, P., & Vilarem, M.-J. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12072-x · Cited by 372 · cited 2×
“In addition, medium formulation (e.g., the addition/omission of serum or specified hormone mixtures) has a significant influence on the morphological development and cell survival of hepatocytes in culture (Pascussi et al., 2000a,b; Sidhu et al., 2004; Turncliff et al., 2004).”
BackgroundSelf-citationChauret, N., Gauthier, A., & Nicoll‐Griffith, D. A. (1998) · PubMed · Cited by 357
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353 · cited 2×
“…of the total P450, contribute to the metabolism of more than 25% of all pharmaceutical drug metabolism (Code et al., 1997; Ekins and Wrighton, 1999; Faucette et al., 2000; Hanna et al., 2000; Hesse et al., 2000; Stresser and Kupfer, 1999) and exhibit high inducibility (Drocourt et al., 2001; Wang…”
BackgroundSelf-citationInduction of CYP2C genes in human hepatocytes in primary culture.
Gerbal‐Chaloin, S., Pascussi, J., Pichard‐Garcia, L., Daujat‐Chavanieu, M., Waechter, F., Fabre, J.-M., Carrère, N., & Maurel, P. (2001) · PubMed · Cited by 345
Self-citationShitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340 · cited 1×
“…transport metabolites, therefore, it is easy to envisage that metabolism and transport also have a high level of interplay, and that inhibition of transporters may influence the amount of drug metabolized HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 185 and vice versa (Shitara et al., 2003).”
BackgroundSelf-citationMadan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.421 · Cited by 338 · cited 2×
“Most researchers in the survey and others (Kostrubsky et al., 1999; Maurel, 1996; Raucy et al., 2004) incubated compounds for only 48 h, whereas others preferred longer periods (Madan et al., 2003; Meunier et al., 2000; Robertson et al., 2000).”
BackgroundSelf-citationPascussi, J. M., Gerbal-Chaloin, S., Drocourt, L., Maurel, P., & Vilarem, M. J. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00483-x · Cited by 330 · cited 2×
“Pretreatment of hepatocytes with low concentrations of dexamethasone (for example, 30 nM), does not cause increased expression of CYP3A or CYP2B per se but serves as a permissive factor allowing a stronger induction by enzyme inducers (Pascussi et al., 2001,2003; Ringel et al., 2002).”
BackgroundSelf-citationRegulation of CYP3A Gene Transcription by the Pregnane X Receptor
Goodwin, B., Redinbo, M. R., & Kliewer, S. A. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.111901.111051 · Cited by 327 · cited 1×
“Inducers of PXR-mediated CYP3A4 include natural glucocorticoids and synthetic steroids as well as a wide spectrum of xenobiotics (Drocourt et al., 2001; Goodwin et al., 2002; Kliewer et al., 2002; Waxman, 1999).”
BackgroundAndersson, T. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631010-00002 · Cited by 326 · cited 8×
“Gene reporter experiments with proximal promoters showed that HNF-3γ transactivated CYP2C8, CYP2C9, and CYP2C19 but not CYP2C18.”
BackgroundInfluentialSteroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Korzekwa, K. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90602-f · Cited by 324 · cited 3×
“Female rats continuously secrete growth hormones that cause them to have female-specific enzymes such as CYP2C12 and steroid 5α-reductase (Parkinson, 2001; Waxman et al., 1991a).”
BackgroundRole of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity
Walgren, J. L., Mitchell, M. D., & Thompson, D. C. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935620 · Cited by 322 · cited 2×
“Chemically reactive metabolites are of particular interest because they play a key role in DILI caused by numerous compounds (Walgren et al., 2005).”
BackgroundThe Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043005001 · Cited by 315 · cited 4×
“In contrast, enzyme(s) not involved in the metabolism of the compound do not need to be studied in clinical studies (Bjornsson et al., 2003).”
BackgroundInfluentialWaring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M., & Ulrich, R. G. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00267-3 · Cited by 313 · cited 1×
“Specific mRNA expression patterns for hepatocellular necrosis, inflammation, hepatitis, fibrosis, microvesicular lipidosis, and bile duct hyperplasia have been identified from in vivo studies (Huang et al., 2004; Waring et al., 2001).”
BackgroundOmeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
Diaz, D., Fabrev, I., Daujat, M., Aubert, B. S., Bories, P., Michel, H., & Maurel, P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90963-2 · Cited by 308 · cited 3×
“There are also species differences in omeprazole induction of CYP1A2, which is induced in human but not in rat, mouse or rabbit hepatocytes (Diaz et al., 1990; Lu and Li, 2001; McDonnell et al., 1992).”
BackgroundSelf-citationBoess, F. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg064 · Cited by 306 · cited 1×
“Compound-associated specific alterations of mRNA expression patterns have also been observed using cultured rat hepatocytes and liver slices (Boess et al., 2003; de Longueville et al., 2003).”
BackgroundPrediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices
Brian Houston, J., & Carlile, D. J. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709002237 · Cited by 306 · cited 3×
“Different in vitro systems such as hepatocytes, liver slices, microsomes, and recombinant microsomes have been compared and found to be equally effective in determining the metabolism and clearance of exclusively CYPmetabolized compounds (Andersson et al., 2001; Houston and Carlile, 1997; Olinga et al., 1998b; Salonen…”
BackgroundSelf-citationPascussi, J., Drocourt, L., Gerbal‐Chaloin, S., Fabre, J., Maurel, P., & Vilarem, M. (2001) · European Journal of Biochemistry · doi:10.1046/j.0014-2956.2001.02540.x · Cited by 302 · cited 4×
“Pretreatment of hepatocytes with low concentrations of dexamethasone (for example, 30 nM), does not cause increased expression of CYP3A or CYP2B per se but serves as a permissive factor allowing a stronger induction by enzyme inducers (Pascussi et al., 2001,2003; Ringel et al., 2002).”
BackgroundInfluentialSelf-citationLi, A. P., Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E., & Silber, P. M. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00088-5 · Cited by 302 · cited 4×
“Selective induction of SULT has been demonstrated in human hepatocytes, the consequence of such induction can lead to failure of the therapeutic efficacy of the compound (Li et al., 1999a).”
BackgroundMethodInfluentialSelf-citationGenomics and Proteomics Analysis of Acetaminophen Toxicity in Mouse Liver
Ruepp, S. U. (2002) · Toxicological Sciences · doi:10.1093/toxsci/65.1.135 · Cited by 301 · cited 2×
“The first successful applications have been identification of potential markers of toxicity using a proteomics approach alone (Fella et al., 2005), or using proteomics in combination with other ‘omics-technologies (Ruepp et al., 2002).”
BackgroundMethodPreclinical Pharmacokinetics: An Approach Towards Safer and Efficacious Drugs
Singh, S. (2006) · Current Drug Metabolism · doi:10.2174/138920006775541552 · Cited by 293 · cited 2×
“…them, changes in enzyme expression, as a consequence of induction or impairment of catalytic enzyme activities due to inhibitory effects of coadministered drugs, appear to be of major importance for the occurrence of adverse drug reactions or lack of therapeutic efficacy (Shah, 2005; Singh, 2006).”
BackgroundCytochromes P450 and experimental models of drug metabolism
Zuber, R., Anzenbacherová, E., & Anzenbacher, P. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00186.x · Cited by 283 · cited 4×
“The CYP2C family also represents a significant proportion of total P450s (2C9, 2C8, 2C19, and 2C18, representing about 20% of the total P450 (Lin and Lu, 1998)) and metabolizes many drugs (Zuber et al., 2002), thus making this enzyme subfamily important to monitor.”
BackgroundInfluentialHENGSTLER, J. G., UTESCH, D., STEINBERG, P., PLATT, K. L., DIENER, B., RINGEL, M., SWALES, N., FISCHER, T., BIEFANG, K., GERL, M., et al. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100100564 · Cited by 277 · cited 2×
“” However, this conclusion is equivocal when one considers that PROD activity in conventional cultures of primary hepatocytes is induced more than 10-fold by phenobarbital (Hengstler et al., 2000).”
BackgroundSelf-citationMcGinnity, D. F., Soars, M. G., Urbanowicz, R. A., & Riley, R. J. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000026 · Cited by 274 · cited 6×
“There are many reports of successful comparisons of drug metabolism in fresh and cryo-preserved human hepatocytes (Hewitt et al., 2001; Li et al., 1999b; McGinnity et al., 2004; Soars et al., 2002) but the ability to cryo-preserve hepatocytes which also attach in culture has been somewhat of a holy grail over the last…”
BackgroundMethodInfluentialThe Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts
Chandra, P., & Brouwer, K. L. R. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026420.79421.8f · Cited by 266
LeCluyse, E. L., Audus, K. L., & Hochman, J. H. (1994) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1994.266.6.c1764 · Cited by 266 · cited 2×
“…excellent morphology and so is well suited to analysis by microscopy (even to the level of electron microscopy), as well as studies of toxicologically relevant interactions between drugs and biliary transporter activity (which have been discussed elsewhere [LeCluyse et al., 1994; Liu et al., 1999].”
BackgroundResultSelf-citationLaishes, B. A., & Williams, G. M. (1976) · In Vitro · doi:10.1007/bf02796495 · Cited by 263 · cited 1×
“…hormone, dexamethasone, is valuable for the long-term preservation of hepatocyte-specific functions, polygonal hepatocyte morphology, as well as the structural integrity of cytoplasmic membranes, especially bile canaliculi-like structures (Yamada et al., 1980; Laishes and Williams, 1976).”
BackgroundTranscriptional Regulation of CYP2C9 Gene
Gerbal-Chaloin, S., Daujat, M., Pascussi, J.-M., Pichard-Garcia, L., Vilarem, M.-J., & Maurel, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107228200 · Cited by 262
Self-citationDifferentiation and isolation of hepatic-like cells from human embryonic stem cells
Lavon, N., Yanuka, O., & Benvenisty, N. (2004) · Differentiation · doi:10.1111/j.1432-0436.2004.07205002.x · Cited by 262 · cited 1×
“…aimed at differentiating different human extra-hepatic stem cells to hepatocytes have been performed by a relatively large number of groups (Avital et al., 2001; Eberhardt et al., 2006; Fiegel et al., 2003; Lavon et al., 2004; Lee et al., 2004; von Mach et al., 2004; Zulewski et al., 2001).”
BackgroundIto, K., & Houston, J. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9015-1 · Cited by 260 · cited 1×
“The 5-fold bias in cryo-preserved hepatocyte predictions should be contrasted with the 9-fold bias observed with human liver microsomes (Ito and Houston, 2005).”
BackgroundSelf-citationPascussi, J.-M., Gerbal-Chaloin, S., Fabre, J.-M., Maurel, P., & Vilarem, M.-J. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12718-6 · Cited by 253 · cited 2×
“In addition, medium formulation (e.g., the addition/omission of serum or specified hormone mixtures) has a significant influence on the morphological development and cell survival of hepatocytes in culture (Pascussi et al., 2000a,b; Sidhu et al., 2004; Turncliff et al., 2004).”
BackgroundSelf-citationHuman Hepatocytes in Primary Culture: The Choice to Investigate Drug Metabolism in Man
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335414 · Cited by 252 · cited 6×
“However, activities in microsomes were higher than those found in hepatocytes prepared from the same liver sample (Gómez-Lechón et al., 2004).”
BackgroundMethodInfluentialSelf-citationWaxman, D. J., Pampori, N. A., Ram, P. A., Agrawal, A. K., & Shapiro, B. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6868 · Cited by 251 · cited 4×
“, 2001) but are of limited value for induction assays due to their lack of liver-specific functions (Dai et al., 1993; Waxman et al., 1991).”
BackgroundInfluentialCode, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K. H., & Waxman, D. J. (1997) · PubMed · Cited by 245
Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes
Hollenberg, P. F. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001387 · Cited by 243 · cited 5×
“However, once thought to be of minor importance and uninducible in humans (Hollenberg, 2002), CYP2B6 may actually constitute at least 5% of the total P450, contribute to the metabolism of more than 25% of all pharmaceutical drug metabolism (Code et al.”
BackgroundInfluentialDai, Y., Rashba-Step, J., & Cederbaum, A. I. (1993) · Biochemistry · doi:10.1021/bi00078a017 · Cited by 240 · cited 2×
“, 2001) but are of limited value for induction assays due to their lack of liver-specific functions (Dai et al., 1993; Waxman et al., 1991).”
BackgroundWilliams, G. M., Bermudez, E., & Scaramuzzino, D. (1977) · In Vitro · doi:10.1007/bf02615128 · Cited by 240
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230 · cited 1×
“It was withdrawn from the market because of liver toxicity and fulminant hepatic failure in several patients (Gitlin et al., 1998; Neuschwander-Tetri et al., 1998).”
BackgroundP-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups
Scala, S., Akhmed, N., Rao, U. S., Paull, K., Lan, L.-B., Dickstein, B., Lee, J.-S., Elgemeie, G. H., Stein, W. D., & Bates, S. E. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.1024 · Cited by 229 · cited 1×
“Cell suspensions can also be used for accumulation and efflux studies (Alvarez et al., 1997; Scala et al., 1997).”
BackgroundIn Vitro Analysis of Human Drug Glucuronidation and Prediction of in Vivo Metabolic Clearance
Soars, M. G., Burchell, B., & Riley, R. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.382 · Cited by 228 · cited 6×
“…comparisons of drug metabolism in fresh and cryo-preserved human hepatocytes (Hewitt et al., 2001; Li et al., 1999b; McGinnity et al., 2004; Soars et al., 2002) but the ability to cryo-preserve hepatocytes which also attach in culture has been somewhat of a holy grail over the last 20…”
BackgroundMethodInfluentialBiliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration
Liu, X., LeCluyse, E. L., Brouwer, K. R., Gan, L.-S. L., Lemasters, J. J., Stieger, B., Meier, P. J., & Brouwer, K. L. R. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.277.1.g12 · Cited by 226 · cited 7×
“It has been shown that sandwich cultures express P-gp transporter proteins, polarized in the bile cannuliculi (Liu et al., 1999).”
BackgroundMethodInfluentialSelf-citationIto, K., & Houston, J. B. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026429.12114.7d · Cited by 224 · cited 1×
“Rat liver microsomes show a 2-fold bias in predictions whereas fresh rat hepatocytes show a minimal bias of 20% (Ito and Houston, 2004).”
BackgroundSelf-citationHickman, D., Wang, J. P., Wang, Y., & Unadkat, J. D. (1998) · PubMed · Cited by 222
Drug Uptake Systems in Liver and Kidney
van Montfoort, J., Hagenbuch, B., Groothuis, G., Koepsell, H., Meier, P., & Meijer, D. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489460 · Cited by 221
Self-citationJover, R., Bort, R., Gómez‐Lechón, M. J., & Castell, J. V. (2002) · The FASEB Journal · doi:10.1096/fj.02-0195fje · Cited by 221 · cited 1×
“CYP3A4 is downregulated by IL-6 (the principal regulator of the hepatic acute-phase response) and this requires activation of the glycoprotein receptor gp130 (Jover et al., 2002).”
BackgroundSelf-citationJover, R. (2001) · Hepatology · doi:10.1053/jhep.2001.22176 · Cited by 216 · cited 1×
“An adenoviral vector was used to study the role of hepatocyte nuclear factor 4 (HNF4) in the regulation of CYPs in human hepatocytes (Jover et al., 2001).”
MethodComparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver
Ellinger-Ziegelbauer, H., Stuart, B., Wahle, B., Bomann, W., & Ahr, H. J. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.02.004 · Cited by 211 · cited 2×
“Investigations of patterns of pathwayassociated genes allowed a correct assignment of tested substances to the groups of “genotoxic” or “nongenotoxic” rat carcinogens (Ellinger-Ziegelbauer et al., 2005).”
BackgroundBrown, H. S., Griffin, M., & Houston, J. B. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011569 · Cited by 211 · cited 3×
“However Km values tend to be lower in cryo-preserved hepatocytes than in microsomes and as a result the particular clearance value obtained for a drug using hepatocytes may be slightly higher or similar to microsomes (Brown et al., 2006; Hallifax et al., 2005).”
BackgroundMethodResultSelf-citationBakke, O. M., Manocchia, M., de Abajo, F., Kaitin, K. I., & Lasagna, L. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90078-0 · Cited by 208 · cited 1×
“These conjugates of carboxylic acid drugs have been studied intensely since several NSAIDs, have been associated with hepatotoxicity (Bakke et al., 1995; Zimmerman, 1994) most of which are carboxylic acids, but share few other structural similarities.”
BackgroundCui, Y., König, J., & Keppler, D. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12502-3 · Cited by 206 · cited 1×
“Cui et al. (2001) demonstrated the expression and localization of basolateral OATP 1B3 and apical MRP2 in double-transfected MDCK cells grown on Transwell membrane inserts (Fig.”
BackgroundLampe, J. W., Bigler, J., Horner, N. K., & Potter, J. D. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00009 · Cited by 205 · cited 3×
“UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations.”
BackgroundIsolation, Characterization, and Transplantation of Bone Marrow-Derived Hepatocyte Stem Cells
Avital, I., Inderbitzin, D., Aoki, T., Tyan, D. B., Cohen, A. H., Ferraresso, C., Rozga, J., Arnaout, W. S., & Demetriou, A. A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5712 · Cited by 203 · cited 2×
“Experiments aimed at differentiating different human extra-hepatic stem cells to hepatocytes have been performed by a relatively large number of groups (Avital et al., 2001; Eberhardt et al., 2006; Fiegel et al., 2003; Lavon et al., 2004; Lee et al., 2004; von Mach et al., 2004; Zulewski et al., 2001).”
BackgroundLu, C., & Li, A. P. (2001) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00162-4 · Cited by 203 · cited 3×
“In contrast, dexamethasone and pregnenalone-16α-carbonitril (PCN) are potent inducers of rat CYP3A1/2 whereas rifampin is a relatively poor inducer of this enzyme (Lu and Li, 2001; Maurel, 1996).”
BackgroundSelf-citationYamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008938 · Cited by 202 · cited 1×
“Initial experiments aimed to optimize methods using fresh rat hepatocytes and subsequent assays were successfully extended to fresh and cryo-preserved human hepatocytes (Liu et al., 1999; Olinga et al., 2001; Sandker et al., 1994; Yamashiro et al., 2006).”
MethodCisplatin-Induced Hepatotoxicity Is Enhanced by Elevated Expression of Cytochrome P450 2E1
Lu, Y., & Cederbaum, A. I. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj031 · Cited by 202 · cited 1×
“The clinical implications of enzyme induction should not be ignored since failure to do so has proven to have serious consequences (Lu and Cederbaum, 2006; Shah, 2005).”
BackgroundMultiple mechanisms in the regulation of ethanol‐inducible cytochrome P450IIE1
Koop, D. R., & Tierney, D. J. (1990) · BioEssays · doi:10.1002/bies.950120906 · Cited by 200 · cited 2×
“Koop and Tierney, 1990; Novak and Woodcroft, 2000; Raucy et al., 2004).”
BackgroundPresent status and perspectives of cell-based therapies for liver diseases
Nussler, A., Konig, S., Ott, M., Sokal, E., Christ, B., Thasler, W., Brulport, M., Gabelein, G., Schormann, W., Schulze, M., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.04.002 · Cited by 197 · cited 1×
“Numerous articles have reported the generation of hepatocyte-like cells from different types of extrahepatic stem or precursor cells (Beerheide et al., 2002; Hengstler et al., HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 211 2005; Nussler et al., 2006).”
BackgroundSelf-citationTroglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195 · cited 1×
“It was withdrawn from the market because of liver toxicity and fulminant hepatic failure in several patients (Gitlin et al., 1998; Neuschwander-Tetri et al., 1998).”
BackgroundCoon, J., Hamilton, G., Jolley, S., Gilbert, D., Barros, S., & LeCluyse, E. (2001) · Cell and Tissue Research · doi:10.1007/s004410100429 · Cited by 193 · cited 1×
“In addition to the extracellular matrix application and media formulation, cell density also has some influence on the morphology of hepatocytes in culture (Hamilton et al., 2001).”
BackgroundSelf-citationLeCluyse, E. L., Bullock, P. L., & Parkinson, A. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00418-8 · Cited by 193 · cited 1×
“The establishment of long-term cultures of primary hepatocytes has long been desired and many efforts have been undertaken to achieve this goal (LeCluyse et al., 1996a,b).”
BackgroundSelf-citationHariparsad, N., Nallani, S. C., Sane, R. S., Buckley, D. J., Buckley, A. R., & Desai, P. B. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269142 · Cited by 192 · cited 2×
“Retrospective studies suggest that induction observed in vivo can be reproduced in vitro and there are numerous reports of good correlations (Drocourt et al., 2001; Faucette et al., 2004; Hariparsad et al., 2004; Kato et al., 2005; Komoroski et al., 2004; Kostrubsky et al., 1998; Li et al., 1997; PichardGarcia et al.,…”
BackgroundDrug metabolism in hepatocyte sandwich cultures of rats and humans
Kern, A., Bader, A., Pichlmayr, R., & Sewing, K.-F. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00204-9 · Cited by 191
Easterbrook, J. D., Lu, C., Sakai, Y., & Li, A. P. (2001) · PubMed · Cited by 190
Self-citationKobayashi, K., Urashima, K., Shimada, N., & Chiba, K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00843-7 · Cited by 188 · cited 1×
“Cells that had been infected with p21 showed differentiated hepatic phenotypes in morphology and increased CYP3A4 and CYP2C9 protein expression (Kobayashi et al., 2002a; Kunieda et al., 2002).”
BackgroundNaritomi, Y., Terashita, S., Kagayama, A., & Sugiyama, Y. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.580 · Cited by 188 · cited 2×
“Almost all predictions for human clearance are made using 120 million cells/g liver weight (Andersson et al., 2001; Bachmann et al., 2003; Bayliss et al., 1999; Davies and Morris 1993; Fisher et al., 2002; Iwatsubo et al., 1997; Lave et al., 1997; McGinnity et al., 2004; Naritomi et al., 2003; Salonen et al., 2003; So…”
BackgroundMethodSquires, E. J., Sueyoshi, T., & Negishi, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407281200 · Cited by 188 · cited 2×
“CAR is thought to be present in the cytosol in its inactive form, bound to endogenous steroids but in the presence of phenobarbitone (PB) or “PB-like” inducers, it is dephosphorylated to trigger its translocation to the nucleus (Kawana et al., 2003; Squires et al., 2004).”
BackgroundLi, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00051-0 · Cited by 181 · cited 2×
“(2003); (4) Lin and Lu (1998);”
BackgroundSelf-citationKomoroski, B. J., Zhang, S., Cai, H., Hutzler, J. M., Frye, R., Tracy, T. S., Strom, S. C., Lehmann, T., Ang, C. Y. W., Cui, Y. Y., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.512 · Cited by 181 · cited 2×
“Retrospective studies suggest that induction observed in vivo can be reproduced in vitro and there are numerous reports of good correlations (Drocourt et al., 2001; Faucette et al., 2004; Hariparsad et al., 2004; Kato et al., 2005; Komoroski et al., 2004; Kostrubsky et al., 1998; Li et al., 1997; PichardGarcia et al.,…”
BackgroundLPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process
Elferink, M. G. L., Olinga, P., Draaisma, A. L., Merema, M. T., Faber, K. N., Slooff, M. J. H., Meijer, D. K. F., & Groothuis, G. M. M. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00071.2004 · Cited by 180 · cited 6×
“The downregulation of mrp2 mRNA expression in rat liver upon lipopolysaccharide treatment was not observed in human liver, although protein expression of MRP2 was decreased, indicating species differences in the regulation of this transporter (Elferink et al., 2004).”
BackgroundInfluentialSelf-citationREGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
Faucette, S. R., Wang, H., Hamilton, G. A., Jolley, S. L., Gilbert, D., Lindley, C., Yan, B., Negishi, M., & LeCluyse, E. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.348 · Cited by 179 · cited 2×
“Retrospective studies suggest that induction observed in vivo can be reproduced in vitro and there are numerous reports of good correlations (Drocourt et al., 2001; Faucette et al., 2004; Hariparsad et al., 2004; Kato et al., 2005; Komoroski et al., 2004; Kostrubsky et al., 1998; Li et al., 1997; PichardGarcia et al.,…”
BackgroundSelf-citationPhase I and II enzyme characterization of two sources of HepG2 cell lines
Hewitt, N. J., & Hewitt, P. (2004) · Xenobiotica · doi:10.1080/00498250310001657568 · Cited by 178 · cited 1×
“Even, HepG2 cells do not express the major metabolizing enzyme activities; they only exhibit some enzyme activities depending on the culture conditions and the source of the cells (Hewitt and Hewitt, 2004).”
BackgroundSelf-citationNew Technologies and Screening Strategies for Hepatotoxicity: Use of In Vitro Models
Dambach, D. M., Andrews, B. A., & Moulin, F. (2005) · Toxicologic Pathology · doi:10.1080/01926230590522284 · Cited by 177 · cited 1×
“When isolated and handled appropriately they express a broad range of metabolizing enzyme activities, hepatic transporters, and other differentiated functions (Dambach et al., 2005; Farkas and Tannenbaum, 2005; Guillouzo, 1998, O’Brien et al., 2004, Gómezlechón et al., 2004,).”
BackgroundTHE ROLE OF CYP2B6 IN HUMAN XENOBIOTIC METABOLISM*
EKINS, S., & WRIGHTON, S. A. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101942 · Cited by 176 · cited 2×
“…constitute at least 5% of the total P450, contribute to the metabolism of more than 25% of all pharmaceutical drug metabolism (Code et al., 1997; Ekins and Wrighton, 1999; Faucette et al., 2000; Hanna et al., 2000; Hesse et al., 2000; Stresser and Kupfer, 1999) and exhibit high inducibility…”
BackgroundWilson, Z. E., Rostami‐Hodjegan, A., Burn, J. L., Tooley, A., Boyle, J., Ellis, S. W., & Tucker, G. T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01881.x · Cited by 174 · cited 3×
“There is some debate as to the hepatocellularity of human and animal livers (Bayliss et al., 1999; Houston, 1994; Wilson et al., 2003).”
BackgroundTHE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES
Austin, R. P., Barton, P., Mohmed, S., & Riley, R. J. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002436 · Cited by 174 · cited 1×
“For the vast majority of drugs, intracellular binding occurs (Austin et al., 2005) and it is necessary to correct for this in order to determine the true drug concentration in the medium, which in turn will be in equilibrium with the intracellular drug concentration available to the enzyme (see Eq.”
BackgroundUridine diphosphoglucuronosyltransferase pharmacogenetics and cancer
Nagar, S., & Remmel, R. P. (2006) · Oncogene · doi:10.1038/sj.onc.1209375 · Cited by 173 · cited 1×
“Many drugs are metabolized by direct conjugation with glucuronic acid (Nagar and Remmel, 2006; Soars et al., 2004) but the potential to induce UDP-glucuronosyl S-transferases (UGTs) is seldom studied.”
BackgroundKretzrommel, A., & Boelsterli, U. A. (1993) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1993.1097 · Cited by 171 · cited 1×
“Kretz-Rommel and Boelsterli (1993) showed that the in vitro covalent binding of diclofenac to hepatocellular proteins (in cultured hepatocytes) was dependent on diclofenac-GlcA (D-GlcA) formation, and inhibition of D-GlcA formation by either borneol or TPHU (7,7,7-triphenylheptyl-UDP) decreased…”
BackgroundPredictability of the covalent binding of acidic drugs in man
Benet, L. Z., Spahn-Langguth, H., Iwakawa, S., Volland, C., Mizuma, T., Mayer, S., Mutschler, E., & Lin, E. T. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90279-c · Cited by 170 · cited 1×
“Several studies have shown that both acyl-glucuronides and acyl-CoAs are able to trans-acylate GSH and proteins (Benet et al., 1993; Bolze et al., 2002; Grillo et al., 2002, 2003; Sidenius et al., 2004) forming thioester-, ester- or amide-bound covalent adducts.”
BackgroundProteome Analysis by Mass Spectrometry
Ferguson, P. L., & Smith, R. D. (2003) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.32.110601.141854 · Cited by 169 · cited 2×
“Uptake of compounds can be directly monitored by incubating suspensions or cultured hepatocytes (either short-term (2 h) or longer term (4 days) with transporter substrates and measuring the amount of compound in lysed cells after a set period (either by radiodetection or LC MS/MS).”
BackgroundMaurel, P. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00417-6 · Cited by 167 · cited 9×
“In contrast, dexamethasone and pregnenalone-16α-carbonitril (PCN) are potent inducers of rat CYP3A1/2 whereas rifampin is a relatively poor inducer of this enzyme (Lu and Li, 2001; Maurel, 1996).”
BackgroundInfluentialSelf-citationShibata, Y., Takahashi, H., Chiba, M., & Ishii, Y. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.892 · Cited by 167 · cited 2×
“Shibata et al. (2002) suggested that hepatocytes should be pooled to give an “average donor”, however, an advantage of single donor incubations is that clearance may be linked to enzyme characteristics, as was demonstrated with four of the six compounds tested by Blanchard et al. (2006).”
BackgroundResultNOVAK, R. F., & Woodcroft, K. J. (2000) · Archives of Pharmacal Research · doi:10.1007/bf02975435 · Cited by 161 · cited 2×
“Koop and Tierney, 1990; Novak and Woodcroft, 2000; Raucy et al., 2004).”
BackgroundGardner-Stephen, D., Heydel, J.-M., Goyal, A., Lu, Y., Xie, W., Lindblom, T., Mackenzie, P., & Radominska-Pandya, A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.340 · Cited by 160 · cited 2×
“There is a large interindividual variability in UGT enzyme activities, possibly due to polymorphisms of the enzyme itself (e.g., UGT2B15*2 (Chung et al., 2005)) or of the regulating nuclear receptor, PXR (Gardner-Stephen et al., 2004).”
BackgroundIrreversible binding of zomepirac to plasma protein in vitro and in vivo.
Smith, P. C., McDonagh, A. F., & Benet, L. Z. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112392 · Cited by 159 · cited 2×
“Studies by Smith et al. (1986) subsequently showed that the acylglucuronides (both the β-1-O-glucuronide and its isomers) of zomepirac were able to trans-acylate serum albumin in vitro.”
BackgroundChallenging Dogma: Thresholds for Genotoxic Carcinogens? The Case of Vinyl Acetate
Hengstler, J. G., Bogdanffy, M. S., Bolt, H. M., & Oesch, F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140219 · Cited by 155 · cited 2×
“Most drugs are metabolized to inactive or less active metabolites in the liver (Arand et al., 2003; Hengstler et al., 2003).”
BackgroundSelf-citationInduction of Drug Metabolising Enzymes: Pharmacokinetic and Toxicological Consequences in Humans
Fuhr, U. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038060-00003 · Cited by 154
AN ASSESSMENT OF UDP-GLUCURONOSYLTRANSFERASE INDUCTION USING PRIMARY HUMAN HEPATOCYTES
Soars, M. G., Petullo, D. M., Eckstein, J. A., Kasper, S. C., & Wrighton, S. A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.140 · Cited by 152 · cited 2×
“However, Soars et al. (2004) found that although UGT isoforms could be statistically significantly increased, the induction varied greatly between donors and was not as large as that observed for CYP1A2 or CYP3A4.”
BackgroundConditions affecting primary cell cultures of functional adult rat hepatocytes
Laishes, B. A., & Williams, G. M. (1976) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/bf02796367 · Cited by 152 · cited 2×
“Once the cells are in culture, the addition of the glucocorticoid hormone, dexamethasone, is valuable for the long-term preservation of hepatocyte-specific functions, polygonal hepatocyte morphology, as well as the structural integrity of cytoplasmic membranes, especially bile canaliculi-like structures (Yamada et al.…”
BackgroundIn Vitro Methods in Pharmaceutical Research
(1997) · Elsevier eBooks · doi:10.1016/b978-0-12-163390-5.x5000-5 · Cited by 149
LeCluyse, E. L., Bullock, P. L., Parkinson, A., & Hochman, J. H. (1996) · Pharmaceutical biotechnology · doi:10.1007/978-1-4899-1863-5_9 · Cited by 147 · cited 1×
“The establishment of long-term cultures of primary hepatocytes has long been desired and many efforts have been undertaken to achieve this goal (LeCluyse et al., 1996a,b).”
BackgroundSelf-citationCytochrome P-450 mRNA Expression in Human Liver and Its Relationship with Enzyme Activity
Rodríguez‐Antona, C., Donato, M. T., Pareja, E., Gómez‐Lechón, M. J., & Castell, J. V. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2499 · Cited by 145 · cited 1×
“Rodriguez-Antona et al. (2001) measured the activities of major drug-metabolizing P450 enzymes in liver microsomes obtained from a human liver bank.”
BackgroundSelf-citationThe Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450
Kostrubsky, V. E., Ramachandran, V., Venkataramanan, R., Dorko, K., Esplen, J. E., Zhang, S., Sinclair, J. F., Wrighton, S. A., & Strom, S. C. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15238-5 · Cited by 141 · cited 2×
“Most researchers in the survey and others (Kostrubsky et al., 1999; Maurel, 1996; Raucy et al., 2004) incubated compounds for only 48 h, whereas others preferred longer periods (Madan et al., 2003; Meunier et al., 2000; Robertson et al., 2000).”
BackgroundCuri-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J. C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., & Fourtanier, G. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38702-1 · Cited by 141 · cited 11×
“3D), HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 167 CYP1A2, CYP2C19, and CYP2C9.”
BackgroundResultInfluentialLau, Y. Y., Sapidou, E., Cui, X., White, R. E., & Cheng, K.-C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1446 · Cited by 140 · cited 1×
“There is evidence from a number of studies (Blanchard et al., 2006; Lau et al., 2002; McGinnity et al., 2004; Shibata et al., 2002; Soars et al., 2002) to support the routine use of cryo-preserved human hepatocytes.”
BackgroundRichert, L., Binda, D., Hamilton, G. A., Viollon‐Abadie, C., Alexandre, E., Bigot-Lasserre, D., Bars, R., Coassolo, P., & LeCluyse, E. L. (2002) · Toxicology in Vitro · doi:10.1016/s0887-2333(01)00099-6 · Cited by 139 · cited 2×
“Culturing hepatocytes in a sandwich configuration between two layers of gelled extracellular matrix proteins, with collagen I and matrigel being the most commonly used, has dramatically prolonged the longevity of cultures displaying hepatocyte-specific functions (Dunn et al., 1991; Richert et al., 2002).”
BackgroundSelf-citationSidhu, J. S., Farin, F. M., & Omiecinski, C. J. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1121 · Cited by 139 · cited 2×
“Indeed, there is evidence that the presence of dexamethasone (Sidhu et al., 1995) and a three dimensional extracellular matrix environment (Sidhu et al., 1993) helps maintain constant levels of cytochrome P450 expression.”
BackgroundKamiya, A., Inoue, Y., & Gonzalez, F. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50212 · Cited by 137 · cited 1×
“It is also the key transcription factor regulating responses to xenobiotics through activation of the PXR gene during fetal liver development (Kamiya et al., 2003).”
BackgroundRichert, L., Liguori, M. J., Abadie, C., Heyd, B., Mantion, G., Halkic, N., & Waring, J. F. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007708 · Cited by 136 · cited 1×
“Basal gene expression in human liver tissue and freshly isolated hepatocytes is reported to be distinctively different from one culture to another, regardless of the culture conditions applied (Richert et al., 2006).”
BackgroundArndt, P., Volk, C., Gorboulev, V., Budiman, T., Popp, C., Ulzheimer-Teuber, I., Akhoundova, A., Koppatz, S., Bamberg, E., Nagel, G., et al. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.3.f454 · Cited by 136 · cited 4×
“identify compounds that have a transporter-dependent uptake for example, cyclosporine A for OATPs, quinidine for OCTs, and glibenclamide for OATPs and OATs (Arndt et al., 2001; Sahi, 2005; Shitara et al., 2002; Uwai et al., 2000).”
MethodInfluentialKostrubsky, V. E. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg217 · Cited by 132
Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor
Daujat‐Chavanieu, M., Peryt, B., Lesca, P., Fourtanier, G., Domergue, J., & Maurel, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91130-i · Cited by 131 · cited 11×
“3D), HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 167 CYP1A2, CYP2C19, and CYP2C9.”
BackgroundInfluentialSelf-citationOcular toxicity in low-dose tamoxifen: A prospective study
Noureddin, B. N., Seoud, M., Bashshur, Z. F., Salem, Z. M. K., Shamseddin, A., & Khalil, A. (1999) · Eye · doi:10.1038/eye.1999.217 · Cited by 130 · cited 1×
“It is noteworthy that low dose tamoxifen treatment has been associated with neurotoxicity, especially optic neuritis (Noureddin et al., 1999), which was consistent with the high sensitivity of astrocytes to tamoxifen toxicity in the IdMOC model.”
ResultArlotto, M. P., Trant, J. M., & Estabrook, R. W. (1991) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(91)06114-i · Cited by 129
Re‐expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells
Jover, R., Bort, R., Gómez-Lechón, M. J., & Castell, J. V. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00746-7 · Cited by 129
Self-citationKlingmüller, U., Bauer, A., Bohl, S., Nickel, P. J., Breitkopf, K., Dooley, S., Zellmer, S., Kern, C., Merfort, I., Sparna, T., et al. (2006) · IEE Proceedings - Systems Biology · doi:10.1049/ip-syb:20050067 · Cited by 127
Self-citationMolecular Mechanism of Nuclear Translocation of an Orphan Nuclear Receptor, SXR
Kawana, K., Ikuta, T., Kobayashi, Y., Gotoh, O., Takeda, K., & Kawajiri, K. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.524 · Cited by 125 · cited 2×
“CAR is thought to be present in the cytosol in its inactive form, bound to endogenous steroids but in the presence of phenobarbitone (PB) or “PB-like” inducers, it is dephosphorylated to trigger its translocation to the nucleus (Kawana et al., 2003; Squires et al., 2004).”
BackgroundDrug Metabolism and Disposition
Silva, M. F. B., IJlst, L., Allers, P., Jakobs, C., Durán, M., de Almeida, I. T., & Wanders, R. J. A. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd · Cited by 125
Harris, A. J., Dial, S. L., & Casciano, D. A. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.11.014 · Cited by 123 · cited 1×
“For instance, aflatoxin B1, dimethylnitrosamine, acetylaminofluorene, and paracetamol all induced characteristic induction of specific transcription factors (E2F1 and Id1) in cultured human hepatocytes (Harris et al., 2004).”
Backgroundde Longueville, F. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg196 · Cited by 123 · cited 1×
“Compound-associated specific alterations of mRNA expression patterns have also been observed using cultured rat hepatocytes and liver slices (Boess et al., 2003; de Longueville et al., 2003).”
BackgroundGeneration of human hepatocytes by stem cell technology: definition of the hepatocyte
Hengstler, J. G., Brulport, M., Schormann, W., Bauer, A., Hermes, M., Nussler, A. K., Fandrich, F., Ruhnke, M., Ungefroren, H., Griffin, L., et al. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.61 · Cited by 123 · cited 1×
“These techniques are being used to construct databases that aim to predict the type of toxicity caused by individual test compounds in vivo, based on analysis of patterns of change in gene expression (Hengstler et al., 2006).”
MethodSelf-citationInduction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract
McDonnell, W. M., Scheiman, J. M., & Traber, P. G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91171-y · Cited by 122 · cited 1×
“There are also species differences in omeprazole induction of CYP1A2, which is induced in human but not in rat, mouse or rabbit hepatocytes (Diaz et al., 1990; Lu and Li, 2001; McDonnell et al., 1992).”
BackgroundNozawa, T., Sugiura, S., Nakajima, M., Goto, A., Yokoi, T., Nezu, J., Tsuji, A., & Tamai, I. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.291 · Cited by 121 · cited 1×
“Nozawa et al. (2004) demonstrated that troglitazone reduced the bile flow within 1 h in isolated perfused rat livers, an effect that was sex-specific and related to the extent of troglitazone sulfate formed.”
BackgroundClinical Pharmacokinetics of Troglitazone
Loi, C., Young, M. A., Randinitis, E. J., Vassos, A. B., & Koup, J. R. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937020-00001 · Cited by 119 · cited 1×
“In humans, troglitazone is predominantly conjugated with sulfate (70% of all metabolites (Loi et al., 1999a,b) and only 3% of orally administered troglitazone is excreted unchanged in the urine.”
BackgroundEvidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib
Paulson, S. K., Engel, L., Reitz, B. A., Bolten, S., Burton, E. G., Maziasz, T. J., Yan, B., & Schoenhard, G. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15037-4 · Cited by 119
Liver‐Specific Gene Expression in Cultured Human Hematopoietic Stem Cells
Fiegel, H. C., Lioznov, M. V., Cortes‐Dericks, L., Lange, C., Kluth, D., Fehse, B., & Zander, A. R. (2003) · STEM CELLS · doi:10.1634/stemcells.21-1-98 · Cited by 117 · cited 2×
“Experiments aimed at differentiating different human extra-hepatic stem cells to hepatocytes have been performed by a relatively large number of groups (Avital et al., 2001; Eberhardt et al., 2006; Fiegel et al., 2003; Lavon et al., 2004; Lee et al., 2004; von Mach et al., 2004; Zulewski et al., 2001).”
BackgroundTuschl, G., & Mueller, S. O. (2005) · Toxicology · doi:10.1016/j.tox.2005.10.017 · Cited by 117 · cited 1×
“As well as gene expression changes over time, there are differences in mRNA levels between the specific cell cultures at a given time-point (Tuschl and Mueller, 2006).”
BackgroundSelf-citationHe, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J., & Woolf, T. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.639 · Cited by 115 · cited 8×
“Alternatively, or in addition, these metabolites may act by depleting intramitochondrial GSH or by shifting the mitochondrial redox-state through inhibition of HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 207 glutathione reductase (Kassahun et al., 1994; Tang et al., 1995).”
BackgroundInfluentialHuman and animal hepatocytes in vitro with extrapolation in vivo
O'Brien, P. J., Chan, K., & Silber, P. M. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.003 · Cited by 114 · cited 1×
“When isolated and handled appropriately they express a broad range of metabolizing enzyme activities, hepatic transporters, and other differentiated functions (Dambach et al., 2005; Farkas and Tannenbaum, 2005; Guillouzo, 1998, O’Brien et al., 2004, Gómezlechón et al., 2004,).”
BackgroundIn Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil
Robertson, P., DeCory, H. H., Madan, A., & Parkinson, A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15146-x · Cited by 114 · cited 4×
“Most researchers in the survey and others (Kostrubsky et al., 1999; Maurel, 1996; Raucy et al., 2004) incubated compounds for only 48 h, whereas others preferred longer periods (Madan et al., 2003; Meunier et al., 2000; Robertson et al., 2000).”
BackgroundInfluentialYoshitomi, S., Ikemoto, K., Takahashi, J., Miki, H., Namba, M., & Asahi, S. (2001) · Toxicology in Vitro · doi:10.1016/s0887-2333(01)00011-x · Cited by 113 · cited 2×
“HepG2 cells stably integrated with specific P450 isoforms have been shown to be responsive to CYP inducers (Allen et al., 2001; Yoshitomi et al., 2001) but are of limited value for induction assays due to their lack of liver-specific functions (Dai et al., 1993; Waxman et al., 1991).”
BackgroundHanna, I. H., Reed, J. R., Guengerich, F. P., & Hollenberg, P. F. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1708 · Cited by 113 · cited 2×
“…to the metabolism of more than 25% of all pharmaceutical drug metabolism (Code et al., 1997; Ekins and Wrighton, 1999; Faucette et al., 2000; Hanna et al., 2000; Hesse et al., 2000; Stresser and Kupfer, 1999) and exhibit high inducibility (Drocourt et al., 2001; Wang et al., 2003; Xie et…”
BackgroundLi, A. P., Bode, C., & Sakai, Y. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.010 · Cited by 112 · cited 2×
“Using this technology, the toxicity of tamoxifen (an anticancer agent with known human toxicity) was determined in primary cells from multiple human organs: liver (hepatocytes), kidney (kidney cortical cells), lung (small airway epithelial cells), central nervous system (astrocytes), blood vessels (aortic endothelial…”
BackgroundSelf-citationDonato, M. T., Castell, J. V., & Gómez‐Lechón, M. J. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80049-x · Cited by 112 · cited 1×
“This variability is markedly higher than that in other species (Donato et al., 1999).”
BackgroundSelf-citationIsolation and culturing of hepatocytes from human livers
Li, A. P., Roque, M. A., Beck, D. J., & Kaminski, D. L. (1992) · Methods in Cell Science · doi:10.1007/bf01409104 · Cited by 111
Self-citationMonospecific Antipeptide Antibody to Cytochrome P-450 2B6
Stresser, D. M., & Kupfer, D. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15215-4 · Cited by 111 · cited 2×
“…the metabolism of more than 25% of all pharmaceutical drug metabolism (Code et al., 1997; Ekins and Wrighton, 1999; Faucette et al., 2000; Hanna et al., 2000; Hesse et al., 2000; Stresser and Kupfer, 1999) and exhibit high inducibility (Drocourt et al., 2001; Wang et al., 2003; Xie et al., 2000).”
BackgroundRunge, D., Runge, D., Jäger, D., Lubecki, K. A., Stolz, D. B., Karathanasis, S. K., Kietzmann, T., Strom, S. C., Jungermann, K. A., Fleig, W. E., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2215 · Cited by 110 · cited 1×
“Investigating CYP induction in serum-free collagen sandwich cultures of primary hepatocytes may confer a more stable expression of CYPs over longer times, resulting in more reproducible results (Runge et al., 2000).”
BackgroundEffects of Troglitazone on HepG2 Viability and Mitochondrial Function
Tirmenstein, M. A. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.131 · Cited by 110 · cited 2×
“(Haskins et al., 2001; Narayanan et al., 2003; Shishido et al., 2003; Tirmenstein et al., 2002).”
BackgroundDrug Interactions that Matter: A Critical Reappraisal
McInnes, G. T., & Brodie, M. J. (1988) · Drugs · doi:10.2165/00003495-198836010-00006 · Cited by 109
Eberhardt, M., Salmon, P., von Mach, M.-A., Hengstler, J. G., Brulport, M., Linscheid, P., Seboek, D., Oberholzer, J., Barbero, A., Martín, I., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.016 · Cited by 108 · cited 2×
“Experiments aimed at differentiating different human extra-hepatic stem cells to hepatocytes have been performed by a relatively large number of groups (Avital et al., 2001; Eberhardt et al., 2006; Fiegel et al., 2003; Lavon et al., 2004; Lee et al., 2004; von Mach et al., 2004; Zulewski et al., 2001).”
BackgroundSelf-citationShitara, Y., Sugiyama, D., Kusuhara, H., Kato, Y., Abe, T., Meier, P. J., Itoh, T., & Sugiyama, Y. (2002) · Pharmaceutical Research · doi:10.1023/a:1014264614637 · Cited by 107 · cited 4×
“identify compounds that have a transporter-dependent uptake for example, cyclosporine A for OATPs, quinidine for OCTs, and glibenclamide for OATPs and OATs (Arndt et al., 2001; Sahi, 2005; Shitara et al., 2002; Uwai et al., 2000).”
MethodInfluentialHargus, S. J., Amouzedeh, H. R., Pumford, N. R., Myers, T. G., McCoy, S. C., & Pohl, L. R. (1994) · Chemical Research in Toxicology · doi:10.1021/tx00040a014 · Cited by 107 · cited 1×
“Further studies by Hargus et al. (1994, 1995) showed that in vivo and in vitro formation of a 110 kDa protein adduct (found to be DPP IV) was also dependent on diclofenac-GlcA formation and could be ameliorated by co-incubation with β-glucuronidase, which hydrolyzes β-1-O-glucuronides.”
BackgroundOrphan Receptor Promiscuity in the Induction of Cytochromes P450 by Xenobiotics
Smirlis, D., Muangmoonchai, R., Edwards, M., Phillips, I. R., & Shephard, E. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005930200 · Cited by 107 · cited 26×
“Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.”
BackgroundInfluentialLavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Pharmaceutical Research · doi:10.1023/a:1012036324237 · Cited by 106 · cited 3×
“Almost all predictions for human clearance are made using 120 million cells/g liver weight (Andersson et al., 2001; Bachmann et al., 2003; Bayliss et al., 1999; Davies and Morris 1993; Fisher et al., 2002; Iwatsubo et al., 1997; Lave et al., 1997; McGinnity et al., 2004; Naritomi et al., 2003; Salonen et al., 2003; So…”
BackgroundMethodGuyomard, C., Rialland, L., Frémond, B., Chesné, C., & Guillouzo, A. (1996) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.0299 · Cited by 106
Self-citationLong-term primary cultures of adult human hepatocytes
Ferrini, J.-B., Pichard‐Garcia, L., Domergue, J., & Maurel, P. (1997) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00072-0 · Cited by 106 · cited 2×
“Human hepatocytes once isolated, are placed in chemically defined culture conditions where they express typical hepatic biochemical functions and contain the entire hepatic drug-metabolizing enzyme system in an integrated form providing an in vitro model that is a very useful tool for anticipating drug metabolism and…”
BackgroundSelf-citationCHUNG, J., CHO, J., YU, K., KIM, J., JUNG, H., LIM, K., JANG, I., & SHIN, S. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.02.006 · Cited by 105 · cited 2×
“, UGT2B15*2 (Chung et al., 2005)) or of the regulating nuclear receptor, PXR (Gardner-Stephen et al.”
BackgroundHuman cytochrome P450s: selectivity and measurement in vivo
SMITH, D. A., ABEL, S. M., HYLAND, R., & JONES, B. C. (1998) · Xenobiotica · doi:10.1080/004982598238859 · Cited by 105 · cited 1×
“clinical practice (Smith et al., 1998, Ingelman-Sundberg, 2005).”
Drocourt, L., Pascussi, J., Assénat, E., Fabre, J.-M., Maurel, P., & Vilarem, M. (2001) · PubMed · Cited by 104
Self-citationSeitz, S., Kretz-Rommel, A., Oude Elferink, R. P. J., & Boelsterli, U. A. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970203+ · Cited by 101 · cited 2×
“showed that when D-GlcA transport into the bile was absent, no formation of what was believed to be the same DDP IV-adduct was seen (Seitz et al., 1998).”
BackgroundMethodMasubuchi, Y., Kano, S., & Horie, T. (2006) · Toxicology · doi:10.1016/j.tox.2006.02.017 · Cited by 100 · cited 1×
“Further evidence for trogliazone being a direct toxicant came from Masubuchi et al. (2006).”
BackgroundCytotoxicity and apoptosis produced by troglitazone in human hepatoma cells
Yamamoto, Y., Nakajima, M., Yamazaki, H., & Yokoi, T. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01432-1 · Cited by 99 · cited 3×
“…whereby troglitazone is bioactivated to the sulfate and quinine (which is found to have some toxic effects, albeit lower than troglitazone itself (Yamamoto et al., 2001)) but detoxified by glucuronidation, as noted using pig hepatocytes which predominantly glucuronidate troglitazone (Kostrubsky…”
BackgroundInfluentialCui, D., Booth-Genthe, C. L., Carlini, E., Carr, B., & Schrag, M. L. (2004) · PubMed · doi:10.1124/dmd.32.11 · Cited by 98
Inactivation of general acyl-CoA dehydrogenase from pig kidney by a metabolite of hypoglycin A.
Wenz, A., Thorpe, C., & Ghisla, S. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68697-7 · Cited by 97
Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants
Huang, Q., Jin, X., Gaillard, E. T., Knight, B. L., Pack, F. D., Stoltz, J. H., Jayadev, S., & Blanchard, K. T. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.12.020 · Cited by 96 · cited 1×
“Specific mRNA expression patterns for hepatocellular necrosis, inflammation, hepatitis, fibrosis, microvesicular lipidosis, and bile duct hyperplasia have been identified from in vivo studies (Huang et al., 2004; Waring et al., 2001).”
BackgroundAcylation of albumin by 1-O-acyl glucuronides.
van Breemen, R. B., & Fenselau, C. (1985) · PubMed · Cited by 93
Chesné, C., & Guillouzo, A. (1988) · Cryobiology · doi:10.1016/0011-2240(88)90040-5 · Cited by 93 · cited 2×
“Cryo-preserved hepatocytes with high viabilities and good metabolic capacities have been reported (Chesne and Guillouzo, 1988; Hewitt et al., 2001; Kafert-Kasting et al., 2006; Li et al.; 1999b; Silva et al., 1999; Skett et al., 1999).”
BackgroundSelf-citationCorlu, A., Kneip, B., Lhadi, C., Leray, G., Glaise, D., Baffet, G., Bourel, D., & Guguen-Guillouzo, C. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.2.505 · Cited by 93 · cited 1×
“Human hepatocyte cultures are normally allowed 48 h to establish good cell-cell contact, a critical characteristic for differentiation (Corlu et al., 1991; Guguen-Guillouzo et al., 1983) and induction potential (Maurel, 1996).”
BackgroundRegulation of Drug and Bile Salt Transporters in Liver and Intestine
Kullak-Ublick, G. A., & Becker, M.-B. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026398 · Cited by 93 · cited 15×
“The downregulation of mrp2 mRNA expression in rat liver upon lipopolysaccharide treatment was not observed in human liver, although protein expression of MRP2 was decreased, indicating species differences in the regulation of this transporter (Elferink et al., 2004).”
BackgroundInfluentialTHE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING
Liu, L., & Pang, K. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001149 · Cited by 93 · cited 1×
“The uptake CLint combined with CLint for efflux and metabolism are cellular processes that make up the total clearance (Liu and Pang, 2005).”
MethodReestablishment of cell polarity of rat hepatocytes in primary culture
Musat, A. I., Sattler, C. A., Sattler, G. L., & Pitot, H. C. (1993) · Hepatology · doi:10.1002/hep.1840180129 · Cited by 92 · cited 1×
“This is in agreement with the previously reported beneficial effects of an extracellular matrix overlay on cell viability and the preservation of normal morphology (Dunn et al., 1991; Musat et al., 1993; LeCluyse et al., 1994).”
ResultEffect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture.
Donato, M. T., Castell, J. V., & Gómez-Lechón, M. J. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06619-x · Cited by 92 · cited 1×
“In summary, it can be reasonably considered that human hepatocytes reflect the heterogeneity of P450 expression in human liver and constitute an invaluable tool for preclinical metabolic and toxicity testing of new chemical entities (Donato et al., 1995; Gomez-Lechón et al., 2004; LeCluyse, 2001).”
Self-citationWang, H., Faucette, S. R., Gilbert, D., Jolley, S. L., Sueyoshi, T., Negishi, M., & LeCluyse, E. L. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.620 · Cited by 91 · cited 2×
“…the metabolism of more than 25% of all pharmaceutical drug metabolism (Code et al., 1997; Ekins and Wrighton, 1999; Faucette et al., 2000; Hanna et al., 2000; Hesse et al., 2000; Stresser and Kupfer, 1999) and exhibit high inducibility (Drocourt et al., 2001; Wang et al., 2003; Xie et al., 2000).”
BackgroundSelf-citationEffect of tadalafil on cytochrome P450 3A4?mediated clearance: Studies in vitro and in vivo
RING, B., PATTERSON, B., MITCHELL, M., VANDENBRANDEN, M., GILLESPIE, J., BEDDING, A., JEWELL, H., PAYNE, C., FORGUE, S., & ECKSTEIN, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.09.006 · Cited by 90 · cited 2×
“Retrospective studies suggest that induction observed in vivo can be reproduced in vitro and there are numerous reports of good correlations (Drocourt et al., 2001; Faucette et al., 2004; Hariparsad et al., 2004; Kato et al., 2005; Komoroski et al., 2004; Kostrubsky et al., 1998; Li et al., 1997; PichardGarcia et al.,…”
BackgroundSidhu, J. S., & Omiecinski, C. J. (1995) · Pharmacogenetics · doi:10.1097/00008571-199502000-00003 · Cited by 90
Tang, C., Lin, J. H., & Lu, A. Y. H. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003236 · Cited by 89 · cited 1×
“The regulation and the mechanisms of induction of CYPs have been extensively reviewed (Hollenberg, 2002; Lin and Lu, 1998; Tang et al., 2005).”
Background
Research works printed but not linked: 48
- Allen S. W., 2001, Drug Metab. Dispos., 29, 1074
- Andersson T. B., 2001, Drug Metab. Dispos., 29, 712
- Arand M., 2003, EXCLI J., 22, 22
- 10.1177/0091270003252519 · doi:10.1177/0091270003252519 · Paper page
- Bort R., 1996, Drug Metab. Dispos., 24, 834
- Bort R., 1996, Drug Metab. Dispos., 24, 969
- Brown H. S., 2006, Drug metab. Dispos., 200, 6
- Chauret N., 1998, Drug Metab. Dispos., 26, 1
- Code E. L., 1997, Drug Metab. Dispos., 25, 985
- Cui Y., 2001, Mol. Pharmacol., 60, 934, 10.1124/mol.60.5.934 · doi:10.1124/mol.60.5.934 · Paper page
- Curi-Pedrosa R., 1994, J. Pharmacol. Exp. Ther., 269, 384
- Donato M. T., 1995, Drug Metab. Disp., 23, 553
- Drew R., 1985, Agents Actions Suppl., 17, 127
- Drocourt L., 2001, Drug Metab. Dispos., 29, 1325
- Easterbrook J., 2001, Drug Metab. Dispos., 29, 141
- Elferink M. G., 2004, Physiol., 287, G1008
- Eneroth A., 2006, Drug Metab. Rev., 38, 61
- Gerbal-Chaloin S., 2001, Drug Metab. Dispos., 29, 242
- Goodwin B., 1999, Mol. Pharmacol., 56, 1329, 10.1124/mol.56.6.1329 · doi:10.1124/mol.56.6.1329 · Paper page
- Grillo M. P., 2001, Drug Metab. Dispos., 29, 1210
- Guengerich F. P, 1990, Basic Life Sci., 53, 381
- Hallifax D., 2006, Drug Metab. Dispos.
- 10.1517/17425255.1.1.61 · DOI · Paper page
- Hewitt N. J., 2001, Drug Metab. Dispos., 29, 1042
- Hewitt N. J., Chem. Biol. Interact.
- Hickman D., 1998, Drug Metab. Dispos., 26, 207
- Hopwood J., 2004, Toxicology, 202, 103
- Klingmüller U., 2006, Systems Biology
- Koganti A., 2005, Drug Metab. Rev., 37, 212
- Kolars J. C., 1991, Hepatology, 13, 197
- Lieu Y. K., 1997, Am. J. Physiol., 272, E359
- 10.1016/j.cbi.2004.09.010 · DOI
- Liu X., 1999, Am. J. Physiol., 277, G12
- Lu A. Y. H, 1998, Drug Metab. Dispos., 26, 1217
- Nomeir A. A., 2001, Drug Metab. Dispos., 29, 748
- Nussler A., 2006, J. Hepatol., 200, 6
- Olinga P., 1998, Drug Metab. Dispos., 26, 5
- Parkinson A, 2001, Casserett and Doull's Toxicology. The Basic Science of Poisons 6th, 133
- Pascussi J. M., 2000, Mol. Pharmacol., 58, 361, 10.1124/mol.58.2.361 · doi:10.1124/mol.58.2.361 · Paper page
- Pascussi J. M., 2000, Mol. Pharmacol., 58, 1441, 10.1124/mol.58.6.1441 · doi:10.1124/mol.58.6.1441 · Paper page
- Ruegg C. E., 1997, In Vitro Technol., 10, 217
- Ruhnke M., 2005, Gastroenterology
- Shimada T., 1994, J. Pharmacol. Exp. Ther., 270, 414
- Stogniew M., 1982, Drug Metab. Dispos., 10, 609
- van Breemen R. B., 1985, Drug Metab. Dispos., 13, 318
- Wahlstrom A., 1989, Drug Metab. Dispos., 17, 218
- Wenz A., 1981, J. Biol. Chem., 256, 9809, 10.1016/S0021-9258(19)68697-7 · DOI
- Zimmerman H. J, 1994, Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Uses 2nd
Cited by
The Many Roles for Fluorine in Medicinal Chemistry
Hagmann, W. K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800219f · Cited by 3,578
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
“In 2007, a review on the ‘‘current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies’’ was published (Hewitt et al. 2007).”
Self-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting
Ma, X., Qu, X., Zhu, W., Li, Y.-S., Yuan, S., Zhang, H., Liu, J., Wang, P., Lai, C. S. E., Zanella, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524510113 · Cited by 872
“The complex microarchitecture and cellular interactions in liver are thought to be essential to long-term hepatocyte functional maintenance as supported by many reports on the loss of liver-specific functions from hepatocytes taken out from the liver (5, 6).”
BackgroundBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Metadata
- Authors
- Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., Guillouzo, A., Tuschl, G., Li, A. P., LeCluyse, E., Groothuis, G. M. M., & Hengstler, J. G.
- Affiliations
- University of Manchester (GB)
- Inserm (FR)
- AstraZeneca (Sweden) (SE)
- Merck KGaA, Darmstadt (Germany) (DE)
- University of Groningen (NL)
- Leipzig University (DE)
- ORCID
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 39
- Issue
- 1
- Pages
- 159-234
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2171534546
- Cited by
- 735
- References
- 352
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 18 · 2023: 17 · 2022: 15 · 2021: 32 · 2020: 33 · 2019: 28 · 2018: 38 · 2017: 31 · 2016: 44 · 2015: 51 · 2014: 55 · 2013: 53 · 2012: 71
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Metabolism Reviews (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary human hepatocytes, drug metabolism, drug transporters, drug clearance, in vitro-in vivo correlation, idiosyncratic hepatotoxicity, drug development
- MeSH terms
- Animals, Carrier Proteins, Cytochrome P-450 Enzyme System, Pharmaceutical Preparations, Humans, Liver Diseases, Metabolic Clearance Rate, Models, Biological, Xenobiotics, Hepatocytes, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.